SuperworthDare Bioscience DARE
- Market cap
- $9.9M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- −119.0%
Dare Bioscience's trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $1M | $1.8M | $9.3K | $22.4K | $41.7K−96% | n/a | $25.4K+173% | n/a | $2.3K−95% | n/a | $152.5K+500% | $187.5K | |
| Cost of revenue | n/a | n/a | n/a | n/a | n/a | n/a | $0 | $0 | n/a | n/a | $242.3K | $319.9K |
| Gross profit | n/a | n/a | n/a | n/a | n/a | n/a | $25.4K | n/a | n/a | n/a | −$89.9K | −$132.3K |
| R&D | $6.7M+50% | $3.8M−71% | $3.4M−33% | $4.9M−18% | $2.7M−60% | n/a | $2.3M−32% | $1.4M−71% | $1.2M−56% | n/a | $660.5K−71% | $242K−83% |
| SG&A | $2.7M+2% | $3.2M−2% | $2.7M−20% | $2.4M−16% | $2M−24% | n/a | $2.3M−14% | $2.4M−3% | $2.5M+22% | n/a | $2.2M−3% | $2.6M+9% |
| −$8.4M+18% | −$5.2M−68% | −$6M−28% | −$7.4M−18% | −$4.7M−44% | n/a | −$4.6M−24% | −$3.8M−48% | −$3.7M−22% | n/a | −$3M−35% | −$3M−23% | |
| Interest expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Net income | −$8.3M+18% | −$5.1M−68% | −$6.8M−16% | $12.9M | −$4.7M−43% | −$5.5M+9% | −$4.4M−35% | −$4M | −$3.6M−24% | −$1.4M−74% | −$3M−32% | −$3M−26% |
| −$1.09+14% | −$0.69−71% | −$0.81−25% | $1.52 | −$0.55−50% | −$0.69+0% | −$0.50−38% | −$0.45 | −$0.28−49% | −$0.10−86% | −$0.21−58% | −$0.20−56% | |
| 7.6M+7% | 7.3M+7% | 8.4M+18% | 8.5M+18% | 8.5M+13% | 8M+10% | 8.8M+5% | 8.9M+5% | 12.8M+50% | 14.3M+78% | 14.5M+66% | 14.9M+68% |
Gross profit: 3 periods, Q1 FY25 to Q2 FY26: not printed by the filing, worked out from its own lines.
Net income: Q2 FY15: not printed by the filing, worked out from its own lines.
EPS, diluted: 9 periods, Q4 FY17 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 4 periods, Q1 FY17 to Q2 FY18: not printed by the filing, worked out from its own lines. 9 periods, Q4 FY17 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Dare Bioscience's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| DAREDare Bioscience | $9.9M | n/m | n/a | n/m | n/m | n/m | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| Peer median | $64.6M | 10.1× | 9.5× | 0.9× | −12% | 9.2% |
More on Dare Bioscience
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .